Information about the topics discussed at the American Society of Hematology (ASH) annual meeting is presented. It highlights the results of the clinical trials regarding the availability of drugs indicated for colorectal cancer. It also claims that intravenous fluoropyrimidine and oral fluoropyrimidine have been the backbone of adjuvant as well as first- and secondline chemotherapy treatment for patients with metastatic colorectal cancer (mCRC).